Dovoljenje za izvajanje neprofitne študije “A multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wildtype advanced ovarian, fallopian tube and primitive peritoneal cancer”
Družba ASUGI obvešča, da je bila pooblaščena za izvajanje neprofitne študije “A multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wildtype advanced ovarian, fallopian tube and primitive peritoneal cancer”, ki bo potekala v Onkološkem socialnem centru ...